Assessment of red cell parameters and interleukin-6 level in chronic kidney disease patients in Sokoto, North-west
DOI:
https://doi.org/10.71637/tnhj.v25i1.852Keywords:
Red cell parameters, interleukin-6, chronic kidney disease.Abstract
Background: Anaemia is one of the conditions associated with chronic kidney disease which has contributed to the morbidity and mortality of patients. This study was undertaken to assess the red cell parameters and interleukin-6 level in patients with chronic kidney disease.
Materials and methods: One-hundred and twenty-two (122) male patients diagnosed with chronic kidney disease (CKD) and 50 control subjects were assessed for red cell parameters and interleukin-6 (IL-6) using standard techniques.
Results: The values of Hb, RBC and MCV of 10.25 ± 5.72g/dL, 3.40 ± 1.34 x1012 /L and 71.17 ± 21.27 fl, respectively in CKD patients were significantly lower compared to 14.35 ± 1.56 g/dL, 5.44 ± 0.62 x1012 /L and 82.5 ± 5.23 fl, respectively in control subjects (p< 0.05) while IL-6 level of 87.49 ± 36.46 ng/L in CKD patients was significantly higher compared to 44.88 ± 13.7 ng/L of control group (p< 0.0001). There were no statistically significant differences in the values of MCHC and MCH between CKD patients and control subjects (p> 0.05). However, stages and age of CKD patients had no effects on the values of RBC parameters (p>0.05) while the age showed significant differences with IL-6 levels (p<0.05).
Conclusion: Significantly lower values of Hb, RBC and MCV, and significantly higher value of IL-6 have been observed among the CKD patients and therefore, the patients are prone to anaemia, possibly microcytic hypochromic anaemia. However, advanced stage of CKD and increasing age of CKD patients could contribute to the development of severe anaemia.
Downloads
References
1. Shastry I, Belurkar S. The spectrum of red cell parameters in chronic kidney disease: A study of 300 cases. J Appl Hematol 2019; 10: 61-66.
2. Khadayate R, Sahu P, Sahu S, Karale S. Study of hematological profile in chronic renal failure patients on hemodialysis in Tertiary Care Hospital. International Journal of Health Sciences and Research 2020; 10(12): 1-7.
3. Chapter 1: Definition and Classification of CKD. Kidney Int Suppl (2011) 2013; 3(1): 19-62.
4. Kidney International Supplements, KDIGO 2012 Clinical Practice Guidelines for Evaluation and Management of Chronic Kidney Disease. Official Journal of the International Society of Nephrology 2013; 3(1): 1-163.
5. KDOQ1 Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39: S1-S246.
6. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease- a systematic review and meta-analysis. PLoS One 2016; 11.
7. Babitt JL, Lin HY. Mechanisms of anaemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634.
8. Eschbach JW, Adamson JW. Anaemia of end-stage renal disease (ESRD). Kidney Int 1985; 28(1): 1-5.
9. Zachee P, Vermylen J, Boogaerts MA. Hematologic aspects of end-stage renal failure. Ann Hematol 1994; 69: 33-40.
10. Locatelli F, Pozzoni P, Del Vecchio L. Recombinant human epoetin beta in the treatment of renal anaemia. Ther Clin Risk Manag 2007; 3(3):433-439.
11. Eschbach JW Jr, Funk D, Adamson J, Kuhn I, Scribner BH, Finch CA. Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 1967; 276: 653-658.
12. Joanne M, Bargman JM, Skorecki K. Disorders of the kidney and urinary tract. In: Harrison’s Principle and Practice of Internal Medicine. 17th ed. Vol 2. New York: McGraw-Hill; 2008:1761-1771.
13. Tennankore KK, Soroka SD, West. KA, Kiberd BA. Macrocytosis may be associated with mortality in chronic hemodialysis patients: A prospective study. BMC Nephrol 2011; 12: 19.
14. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M. IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia-the good, the bad, and the ugly, Kidney International 2005; 67:1216-1233.
15. Herbelin A, Urena P, Nguyen AT et al. Elevated circulating level of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39: 954-960.
16. Cavaillon JM, Poignet JL, Fitting C et al. Serum interleukin-6 in long-term haemodialysed patients. Nephron 1992; 60: 307-313.
17. Vardhan-Raj S, Zhou X, Bueso-Ramos CE, Patel S, Benjamin RS, Nguyen M. Interleukin-6, hepcidin and other biomarkers in anaemia of chronic disease and chemotherapy induced anaemia (CIA): potential therapeutic targets. Blood 2012; 120(21): 2086. https://doi.org/10.1182/blood.V120.21.2086.2086
18. Akchurin O, Patimo E, Dalal V, Meza K, Batia D, Brovender S, Zhu Y-S, Cunningham-Rundles S, Perelstein E, Kumar J, Rivella S, Choi ME. Interleukin-6 contributes to the development of anaemia in Juvenile CKD. Kidney International Reports 2019; 4: 470-483.
19. Akokuwebe ME, Idemudia ES. Prevalence and knowledge of kidney disease risk factors among Nigerians resident in Lagos State metropolitan district South-west Nigeria. Annals of African Medicine 2023; 22(1): 18-32.
20. Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for the prevalence studies. Arch Orofacial Sci 2006; 1 9-14.
21. Iyawe IO, Adejumo OA. Hematological profile of predialysis chronic kidney disease patients in tertiary hospital in Southern Nigeria. Journal of Medicine in the Tropics 2018; 20(1): 36-41.
22. Ahmed J, Khan MT, Hameed B. Hematological profile in patients with chronic kidney disease in Pakistan: a cross-sectional research study. Journal of the Egyptian Society of Nephrology and Transplantation 2021; 21(1): 57-63.
23. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212-1218.
24. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M et al. CRIC study investigation: Association between albuminuria, kidney function and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012; 7: 1938-1946.
25. Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton) 2010; 15(3): 344-349.
Published
Issue
Section
License
Copyright (c) 2025 Momodu Imoru, Zainab Ibrahim Ishaq, Hamidu Muhammad Liman
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
